cep-1347

Small moleculeexperimental

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2002 (NCT00040404)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCSCc1ccc2c(c1)c1c3c(c4c5cc(CSCC)ccc5n5c4c1n2[C@H]1C[C@](O)(C(=O)OC)[C@]5(C)O1)CNC3=O
Mol. weight
615.78 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3,9-bis((ethylthio)methyl)-k-252a
  • 3,9-bis(etsm)-k-252a
  • cep1347
  • cep1347
  • cep1347
  • cep 1347
  • cep-1347
  • cep-1347
  • cep-1347
  • cep-1347
  • cep-1347
  • kt-1575
  • kt-1575
  • kt7515
  • kt 7515
  • kt-7515

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00040404Phase 2/Phase 3 (Phase 3)Mar 1, 2002Cephalon, Lundbeck, The Parkinson Study Group
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
CephalonFor profit1112002
LundbeckFor profit1012002
The Parkinson Study GroupAcademic/Hospital1012002
3 organizations
Page 1 / 1